Publication: Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy
Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy
Date
Date
Date
Citations
Zafar, S., Parviainen, S., Siurala, M., Hemminki, O., Havunen, R., Tähtinen, S., Bramante, S., Vassilev, L., Wang, H., Lieber, A., Hemmi, S., de Gruijl, T., Kanerva, A., & Hemminki, A. (2016). Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy. OncoImmunology, 6(2), e1265717. https://doi.org/10.1080/2162402X.2016.1265717
Abstract
Abstract
Abstract
Vaccination with dendritic cells (DCs), the most potent professional antigen-presenting cells in the body, is a promising approach in cancer immunotherapy. However, tumors induce immunosuppression in their microenvironment that suppresses and impairs the function of DCs. Therefore, human clinical trials with DC therapy have often been disappointing. To improve the therapeutic efficacy and to overcome the major obstacles of DC therapy, we generated a novel adenovirus, Ad3-hTERT-CMV-hCD40L, which is fully serotype 3 and expresses hCD40L
Metrics
Views
Additional indexing
Creators (Authors)
- Zafar, Sadia
- Parviainen, Suvi
- Siurala, Mikko
- Hemminki, Otto
- Havunen, Riikka
- Tähtinen, Siri
- Bramante, Simona
- Vassilev, Lotta
- Wang, Hongjie
- Lieber, Andre
- Hemmi, Silvio
- de Gruijl, Tanja
- Kanerva, Anna
- Hemminki, Akseli
Volume
Volume
Volume
Number
Number
Number
Page range/Item number
Page range/Item number
Page range/Item number
Item Type
Item Type
Item Type
In collections
Language
Language
Language
Publication date
Publication date
Publication date
Date available
Date available
Date available
ISSN or e-ISSN
ISSN or e-ISSN
ISSN or e-ISSN
OA Status
OA Status
OA Status
Publisher DOI
Metrics
Views
Citations
Zafar, S., Parviainen, S., Siurala, M., Hemminki, O., Havunen, R., Tähtinen, S., Bramante, S., Vassilev, L., Wang, H., Lieber, A., Hemmi, S., de Gruijl, T., Kanerva, A., & Hemminki, A. (2016). Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy. OncoImmunology, 6(2), e1265717. https://doi.org/10.1080/2162402X.2016.1265717
